Neurometrix (NASDAQ:NURO) is set to post its quarterly earnings results before the market opens on Wednesday, October 17th.

Neurometrix (NASDAQ:NURO) last released its earnings results on Thursday, July 19th. The medical device company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.39. Neurometrix had a negative net margin of 27.12% and a negative return on equity of 77.46%. The company had revenue of $3.75 million during the quarter.

NURO stock opened at $1.28 on Thursday. Neurometrix has a 12-month low of $1.11 and a 12-month high of $2.96. The company has a market capitalization of $9.78 million, a price-to-earnings ratio of -0.11 and a beta of 0.33.

Separately, Zacks Investment Research downgraded shares of Neurometrix from a “buy” rating to a “hold” rating in a research report on Thursday, September 27th.

Neurometrix Company Profile

NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.

Read More: What are trading strategies for the 52-week high/low?

Earnings History for Neurometrix (NASDAQ:NURO)

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with's FREE daily email newsletter.